|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Cytotoxic Therapies - Market growth will slow due to increasing genericization
Datamonitor, June 2009, Pages: 127
The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Scope
- In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU and Japan, plus a rest of world snapshot
- Cytotoxic therapy sales forecasts for brands and generics from 2008 to 2018
- Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
- Assess the strategies of several leading players in the cytotoxics market
Highlights of this title
The cytotoxics market was worth $13.8 billion in 2008 across the seven major pharmaceutical markets, and is forecast to grow to $18.7 billion by 2018, achieving a CAGR of 3.1%. The launch of Dacogen (decitabine; Eisai/Johnson & Johnson) and Vidaza (azacitidine; Celgene) in the 5EU and Japanese markets will contribute significantly to this growth.
In 2008, Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) were the top three cytotoxics, with sales over $1 billion. Despite facing patent expiry during the forecast period and guaranteed generic entry, Taxotere and Eloxatin will remain in the top three in 2018, along with Dacogen.
The key events to impact the cytotoxics market during the forecast period are the launch of new drugs, expansion into new indications and patent expiries. Several blockbuster products with annual sales of over $1 billion are due to undergo patent expiry during the forecast period, however, generic entry will ensure continued market growth.
Key reasons to purchase this title
- Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
Customers who bought this item also bought
Cytotoxic Therapies Market Forecast
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Commercial Perspectives: Cytotoxics - Third-Generation Cytotoxics To Offset Taxol’s Generic Woes
Forecast Insight: Top 20 Cancer Therapy Brands
Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics
Market Dynamics 2001: Cytotoxics
Antihormonal Therapy Cancer Brands - Careful Lifecycle Management Needed to Preserve Brand Dominance
Generic Benchmarking: Brand Erosion at Patent Expiry
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion At Patent Expiry
Stakeholder Insight: Lung Cancer - Third-Generation Cytotoxics Set to Dominate the Market
|
|
|
|
